[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kaiser Clinic and Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":103},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100630422","autologous-svf-therapy-for-type-2-diabetes-100630422",false,"NCT07487467","Autologous SVF Therapy for Type 2 Diabetes","Evaluation of Autologous Adipose-Derived Stromal Vascular Fraction Obtained by 1210-nm Laser Photostimulation for the Treatment of Type 2 Diabetes Mellitus","LASER-DM2 Tria","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Both sexes\n* Diagnosis of Type 2 Diabetes Mellitus for less than 10 years\n* BMI ≥ 25 kg\u002Fm²\n* HbA1c between 7.5% and 9.5%\n* C-peptide \\> 1.0 nmol\u002FL\n* Use of metformin and\u002For pioglitazone, with or without sulfonylurea\n\nExclusion Criteria:\n\n* Type 1 Diabetes Mellitus or autoimmune diabetes\n* Positive anti-GAD antibodies\n* Pregnancy or breastfeeding\n* Use of insulin therapy\n* Use of SGLT2 inhibitors\n* Use of DPP-4 inhibitors\n* Use of GLP-1 receptor agonists\n* Unknown duration of diabetes","ALL","18 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","This prospective clinical study aims to evaluate the safety and efficacy of autologous adipose-derived stromal vascular fraction (SVF), enriched with mesenchymal stem cells (ADSCs), for the treatment of Type 2 Diabetes Mellitus (T2DM).\n\nAdipose tissue will be harvested using a 1210-nm diode laser-assisted selective photochemical stimulation technique (One-STEP™ method), followed by centrifugation without enzymatic digestion. The isolated SVF will be injected endoluminally into the duodenal submucosa during the same surgical procedure.\n\nFive adult patients with T2DM will be followed for six months to assess metabolic control, pancreatic function, and quality of life outcomes.",[27],"Diabetes Mellitus, Type 2",[29,30,31,32,33],"Adipose-Derived Stem Cells","Stromal Vascular Fraction","Mesenchymal Stem Cells","GLP-1","Regenerative Medicine","RECRUITING","2026-03-17",{"date":37,"type":38},"2026-03-23","ACTUAL",{"date":40,"type":38},"2025-01-20",{"date":42,"type":21},"2026-12-31",{"name":44,"class":45},"Kaiser Clinic and Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":75,"locationsCount":46},"100626828","continuous-glucose-monitoring-with-ican-i3-in-post-bariatric-patients-with-late-dumping-syndrome-100626828","NCT07440706","Continuous Glucose Monitoring With iCan i3 in Post-Bariatric Patients With Late Dumping Syndrome","A Prospective Randomized Study Evaluating the Efficacy and Safety of the iCan i3 Continuous Glucose Monitoring System in Post-Bariatric Patients With Late Dumping Syndrome","iCan3 Dumping","Inclusion Criteria:\n\n* Age 18-65 years\n* History of Roux-en-Y gastric bypass ≥12 months\n* Clinical diagnosis of late dumping syndrome\n* Stable body weight (\\\u003C5% variation in last 3 months)\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Diagnosis of diabetes mellitus under treatment\n* Use of antidiabetic medications (except acarbose)\n* Pregnancy or breastfeeding\n* Cognitive impairment affecting study participation\n* Known hypersensitivity to CGM adhesives\n* Conditions increasing risk of hypoglycemia (e.g., prolonged fasting)\n* Active or prior malignancy\n* Need for imaging procedures during study period","65 Years",{"count":57,"type":21},60,[24],"Late dumping syndrome is a common complication following Roux-en-Y gastric bypass, characterized by postprandial hypoglycemia with significant impact on patient safety and quality of life. Traditional capillary glucose monitoring has limited ability to detect rapid glycemic fluctuations.\n\nThis prospective randomized study aims to evaluate the efficacy and safety of the iCan i3 continuous glucose monitoring (CGM) system compared to conventional capillary glucose monitoring in detecting hypoglycemic events in post-bariatric patients with late dumping syndrome.\n\nParticipants will be randomized into two groups: one using CGM and one using standard fingerstick monitoring, and followed for 60 days. Clinical outcomes, hypoglycemia frequency, symptom correlation, and quality of life will be assessed.",[61,62],"Dumping Syndrome","Post-bariatric Hypoglycemia",[64,65,66,67,68],"Late Dumping Syndrome","Post-Bariatric Hypoglycemia","Continuous Glucose Monitoring","Roux-en-Y Gastric Bypass","Hypoglycemia","2026-02-23",{"date":71,"type":38},"2026-02-27",{"date":73,"type":38},"2025-10-15",{"date":42,"type":21},{"name":44,"class":45},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":46},"100576433","endoscopic-treatment-of-overweight-and-mild-obesity-with-orbera365-100576433","NCT06785233","Endoscopic Treatment of Overweight and Mild Obesity with ORBERA365","Endoscopic Treatment of Overweight and Mild Obesity Using a 12-month Non-adjustable Intragastric Balloon (ORBERA365)","ORBERA365","Inclusion Criteria:\n\n* Participants with a Body Mass Index (BMI) above 27 kg\u002Fm²,\n* both sexes,\n* aged 18 years or older,\n* who consent to their participation by signing an Informed Consent Form and\n* agree to the implantation of the Orbera365® balloon at Kaiser Clinic and the Faculty of Medicine of ABC (FMABC)\u002FHospital Mario Covas.\n\nExclusion Criteria:\n\n* Relative or absolute contraindications for this procedure, such as hiatal hernia (\\> 3 cm),\n* Los Angeles grade erosive esophagitis,\n* peptic ulcer,\n* prior gastric surgery,\n* substance dependence (alcohol or illicit drugs),\n* continuous anticoagulant or anti-inflammatory therapy, and those with\n* positive urease test results until treatment is completed and evidence of resolution is provided or follow-up is lost.",true,{"count":86,"type":21},30,[24],"INTRODUCTION: Obesity is a critical health condition associated with high rates of morbidity and mortality. Conservative therapies such as dietary restriction, physical exercise, and pharmacological treatments have not prevented the rising incidence of obesity. Bariatric surgery, while effective, is limited to a relatively small proportion of the global obese population due to its strict indications and the risk of early and late postoperative complications. To address this gap, bariatric endoscopy therapies have emerged, offering less invasive, reversible, repeatable, and more cost-effective treatment options. The introduction of the intragastric balloon (IGB) in the 1980s marked the development of a minimally invasive, non-surgical, and safe procedure with low complication rates. OBJECTIVE: To evaluate the weight loss efficacy in overweight and Class I obese patients through the implantation of a 12-month non-adjustable intragastric balloon. METHODS: This prospective study involved overweight patients (BMI \\> 27 kg\u002Fm²) undergoing intragastric balloon treatment and multidisciplinary follow-up at the Bariatric Endoscopy Clinic of the Faculty of Medicine of ABC (FMABC) over a 12-month period. EXPECTED RESULTS: Weight loss following intragastric balloon implantation and improvement in metabolic indices.",[90,91],"Obesity","Obesity, Morbid",[93,94],"obesity","Intragastric Balloon","2025-01-17",{"date":97,"type":38},"2025-01-21",{"date":99,"type":21},"2025-01",{"date":101,"type":21},"2026-02",{"name":44,"class":45},""]